Anti-BCMA bispecific antibody(DM16)(Discontinued)
Figure 1. The basic principle of BiTE cell killing assay. The BiTE molecule can effectively bring T cells to tumor target cells and stimulate tumor cell killing activity of T cells.
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Rabbit scfv |
| Purification : | Purified from cell culture supernatant by affinity chromatography |
| Content : | Preservative: 0.1% Procline 300 Constituents: 50% Glycerol; PBS, pH 7.4; 0.1% BSA Not Sterile |
| Storage condition : | Store at -20°C for 12 months (Avoid repeated freezing and thawing) |
| Alternative Name : | TNFRSF17, CD269, BCM, BCMA |
| Immunogen Information : | Recombinant human BCMA (Met1-Ala54) produced by using human HEK293 cells |
BiTE bispecific antibody is an Engineered fusion protein constructed from two single-chain variable fragments (scFvs) of different monoclonal antibodies. One of the scFvs will be constructed from an anti-CD3 monoclonal antibody, and the other scFv fragment which linked by a linker region will be made from an anti-Tumor cell specific monoclonal antibody.The B-cell maturation protein (BCMA or BCM) is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
Recommended Dilutions FACS 1/100; MMTumor cell killing
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
